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ABSTRACT
Objective: The objective of this study was to report the stability of antiviral drug, daclatasvir (DCV) based on the information obtained from forced 
degradation studies and characterization of degradation products (DPs) by tandem mass spectrometry (MS/MS) analysis.
Methods: Chromatographic separation was achieved on Shimadzu liquid chromatography (LC) 20 AD high-performance LC system with photodiode array 
detector having Kromasil C18 (250 mm×4.6 mm×5 μm) with isocratic elution of a mobile phase composed of ammonium acetate buffer (pH 4.5) and 
acetonitrile in a ratio of 50:50 at 315 nm. The drug was subjected to forced hydrolytic, oxidative, photolytic, and thermal stress in accordance with the ICH 
guideline Q1A (R2). The drug showed degradation under acidic and basic hydrolytic conditions by forming two DPs. The DPs were characterized using LC–
MS/MS studies and the pathways of fragmentation are proposed. Validation of the developed method was carried out in accordance with ICH guidelines.
Results: Two DPs were identified, DP-1 as (S)-1-((S)-2-(5-(4’-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-
imidazol-5-yl)-[1,1’-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-aminium and DP-2 as (S)-2-(5-(4’-(2-((S)-1-((S)-2-
((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-[1,1’-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-ium.
Conclusion: The method proved to be simple, accurate, precise, specific, robust, and less time consuming and can be applied for the determination of 
DCV in bulk and marketed formulation.
Keywords: Daclatasvir, Stress degradation, Characterization, Degradation products, Liquid chromatography–mass spectrometry.
INTRODUCTION
The quality of the drugs comprehends the potency, uniformity, purity, 
pharmacological action, stability, etc. Therefore, it becomes essential for 
the manufacturer to maintain the quality and produce effective, safe, and 
non-toxic forms of drugs by developing newer analytical methods [1]. The 
present ICH stability testing guideline requires reporting, identification, 
and characterization of the degradation products (DPs) [2]. In parallel, 
the ICH guidelines on impurities [3] require characterization of all DPs 
formed in drug products at ≥0.1%. However, as DPs generated during 
storage may be at very low levels (~0.1–0.5%, w/w), stress studies are 
suggested to generate them in higher amounts [4]. Therefore, today, focus 
is on techniques that allow the characterization of very low quantities of 
DPs, against the conventional process of isolation and spectral analysis, 
which is tedious and time consuming. Tandem mass spectrometry (MS/
MS) (multistage MS) and liquid chromatography (LC) coupled with 
MS (LC–MS, LC–MS/MS) becoming the most versatile techniques for 
characterization of pharmaceutical DPs and impurity profiling [5].
Daclatasvir (DCV), a non-structural 5A protein inhibitor, combined with 
sofosbuvir, is indicated for adult patients with chronic HCV genotype 3 
regardless of treatment or cirrhosis status [6]. DCV is a white to yellow 
crystalline solid having chemical formula C40H50N8O6. Its structural 
formula is given in Fig. 1.
According to literature survey, there are only few reports on the 
use of stability-indicating reverse-phase high-performance LC (RP-
HPLC) method for the study of degradation behavior of DCV [7-10]. 
Recently, isolation and characterization of degraded products have 
been reported [11]. There are no reports available on characterization 
of alkaline hydrolytic DP to the best of our knowledge. Hence, the 
objective of the current study was to develop stability-indicating RP-
HPLC method for estimation of DCV in tablet formulation to decrease 
the retention time and run time of analysis.
The present manuscript describes the (1) degradation behavior of 
DCV under hydrolysis (acid, base, and neutral), oxidation, photolysis, 
and thermal stress conditions, (2) separate the drug and its DPs on a 
reversed-phase C18 column, LC method conditions were optimized, 
(3) method validation, (4) characterization of DPs, and (5) proposed 
fragmentation pathway of DPs using LC–MS/MS.
METHODS
Chemicals and reagents
Pure sample of DCV was purchased from Taj Mahal Vision Chemicals Pvt. 
Ltd., Mumbai, India. Analytical reagent grade ammonium acetate, glacial 
acetic acid, orthophosphoric acid, hydrochloric acid (HCl), sodium 
hydroxide (NaOH), and hydrogen peroxide (H2O2) were purchased from 
HiMedia Laboratories Pvt., Ltd., Mumbai, India. LC–MS grade methanol 
and acetonitrile were procured from Sigma-Aldrich, Bengaluru, India. 




The chromatographic analysis was performed on LC 20 AD separation 
module HPLC system (Shimadzu Pvt., Ltd., Mumbai) consisting 
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of quaternary gradient pump with an in-line degasser, a column 
compartment with temperature control and a photodiode array (PDA) 
detector. Chromatography data were acquired using LC solutions 
software. To dissolve the samples, an ultrasonicator SI 1432 (Wensar 
Weighing Scales Ltd., Mumbai) was used. LI 120 pH meter (Elico 
Ltd., Hyderabad) was used. A precision water bath equipped with 
MV controller (i-therm, Biomedica, India) capable of controlling the 
temperature within ±1°C was used for generating hydrolytic DPs. 
Thermal stress studies were carried out using a hot air oven Biotechnics 
BTI-20D, Mumbai, India). For photodegradation study, ultraviolet (UV) 
chamber used was to be of BIT make (model no. 49).
MS
LC–MS studies were carried out on an Agilent G1329B LC instrument 
(Agilent Technologies, USA) hyphenated to a quadrupole time-of-flight 
(Q-TOF) MS (Q-TOF LC–MS G6540B series, Agilent Technologies, USA) 
coupled with an electrospray ionization (ESI) source. The MS data 
were acquired using MassHunter Workstation software. The typical 
operating source conditions for MS scan of DCV and its DPs in positive 
ESI mode were optimized as follows: Fragmentor voltage was set at 
170 V, the capillary voltage at 3500 V, skimmer at 60 V, and nitrogen 
was used as the drying (320°C, 10 L/min) and nebulizing (45 psi) gas. 
All the spectra were recorded at an average of 20–25 scans.
Preparation of buffer
About 3.85 g of ammonium acetate and 2.8 ml of glacial acetic acid were 
added to 500 ml volumetric flask and volume was made with double 
distilled water. The pH (4.5) was adjusted with orthophosphoric acid. 
The solution was filtered through 0.45 μ membrane filter and then 
sonicated in a sonicator for 15 min.
Preparation of mobile phase
Buffer (50%) and acetonitrile (50%) were mixed and then filtered 
through 0.45 µ filter under vacuum filtration and degassed in an 
ultrasonicate water bath for 15 min.
Method validation
The analytical method was validated with respect to parameters such 
as specificity, linearity, limit of quantification (LOQ), limit of detection 
(LOD), precision, accuracy, and robustness [12-14].
Stress decomposition studies
To determine the stability-indicating ability of developed HPLC method, 
in-house tablet formulation powder, active pharmaceutical ingredient 
powder, and placebo sample were stressed under various conditions as 
per ICH guidelines. A stock solution was prepared by dissolving 60 mg 
DCV in 100 ml volumetric flask with mobile phase to get concentration 
of 600 μg/ml. In all cases, 1 ml of an aliquot of the above stock solution 
was transferred into a 10 ml volumetric flask. Added 3 ml of stressor to 
it. All hydrolytic studies were conducted at 80°C.
The oxidative study was carried out in 30% (v/v) H2O2 at room 
temperature for 7 days. Hydrolytic decomposition of the drug was 
carried out in 5 N HCl and 2 N NaOH at 80°C for 3 h and 1 h, respectively, 
and in the water, refluxing at 80°C for 24 h. Effect of dry heat (thermal 
degradation) and light (photodegradation) was studied on solid state. 
In case of thermal stress testing, the drug was sealed in glass vials and 
placed in a thermostatic block at 80°C for 1 h. During photodegradation, 
the solid drug powder was exposed to UV light (254 nm) along with 
control samples (covered with aluminum foil). The same stress 
conditions were applied to placebo solution. All degradation samples 
after requisite exposure to stress conditions were diluted with methanol 
to obtain the concentration of individual drug as 60 µg/ml.
Sample preparation
A total of 20 tablets of DCV were weighed and average weight was 
calculated for each tablet. Then, the tablets were powdered and weight 
equivalent to one tablet (60 mg) was measured. It was transferred into a 
100 ml volumetric flask; 50 ml of the mobile phase was added, sonicated 
for 25 min. Final volume was made with the mobile phase and filtered. 
1 ml was pipetted out from the filtered solution into a 10 ml volumetric 
flask and final volume was made with the mobile phase.
RESULTS AND DISCUSSION
Optimization of LC–MS conditions
The main aim of this work was to separate DCV and its DPs. During the 
optimization process, preliminary experiments were carried out on 
HPLC using Kromasil C18 column (250 mm×4.6 mm×5 μm). For the 
selection of mobile phase, various mobile phases such as methanol/
water and acetonitrile/water in different proportions were tried in 
an isocratic mode. The peaks corresponding to drug and DPs did not 
resolve completely and tailing was noticed. To get acceptable separation 
between the drug and its DP, ammonium acetate buffer was used. Further 
studies were carried out using varied proportions of acetonitrile (a) and 
ammonium acetate buffer (b). To optimize the method, pH of the buffer, 
flow rate, and composition of the mobile phase were systematically 
varied. Finally, we achieved good resolution of peaks with acceptable 
shape with ammonium acetate buffer (pH 4.5) and acetonitrile in a 
ratio of 50:50, in an isocratic mode. The flow rate 0.8 ml/min, column 
temperature 25°C, at a wavelength of 315 nm, and injection volume 
20 μl were found to be suitable to achieve the separation of DCV and 
its DP (Fig. 2). As the above-mentioned good resolution of the drug 
and its DP was observed with C-18 column, the same column was used 
for throughout HPLC analysis. The developed method possesses the 
advantages of simplicity as well as rapid determination.
Fig. 1: Chemical structure of daclatasvir
Fig. 2: Chromatogram shows the separation of degradation 
products (DP-1 to DP-2) and daclatasvir in the mixture of stressed 
sample
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The optimized LC method was validated with respect to various 
parameters outlined in the ICH guideline [12] and was extended to 
LC–MS/MS studies. The chromatographic conditions used for LC–MS 
analysis were similar to that of the LC-PDA analyses, except injection 
volume was 0.20 μl.
Method validation
Specificity
The ability of the analytical method to measure the analyte concentration 
accurately in the presence of all potential DPs is known as specificity. 
The specificity of the developed method toward the drug was studied 
by the determination of purity for drug peak in stressed sample. The 
study of resolution factor was also done and was found to be >2. The 
drug and DP peaks were found to be pure from peak purity data. Peak 
purity and resolution factor data are given in Table 1.
Linearity
Linearity test solutions were prepared at seven concentration levels 
from stock solution (30, 60, 90, 120, 150, 180, and 210 μg/ml). The 
least squares linear regression analysis was performed to study the 
relationship between peak area and concentration. The calibration 
curve was drawn by plotting DCV average area for triplicate injections 
and the concentration expressed as a percentage. Good linearity was 
observed in the concentration range from 30 to 210 μg/ml of DCV. The 
data were subjected to statistical analysis using a linear regression 
model, the linear regression equation and correlation coefficient 
(r2) were y=59136x–100914 and 0.9999, respectively. These results 
indicate good linearity. The LOD and LOQ were measured at a signal-
to-noise ratio of 3:1 and 10:1, respectively. The LOD and LOQ were 
1.21 μg/ml and 3.68 μg/ml.
Precision
The precision of the method was performed by intraday and interday 
precision studies. Intraday precision studies were performed by 
injecting the drug in hexaplicate on the same day. Interday precision 
was checked by repeating the studies on 3 different days.
The results of intraday and interday precision studies are presented in 
Table 2. The RSD values for intraday and interday precision studies were 
<0.35 and 0.70, respectively, indicating that developed method is precise.
Accuracy
Accuracy of the method was studied by employing the standard addition 
method, at three different levels (80%, 100%, and 120%). The recovery 
studies were carried out in triplicate and from the difference between 
peak areas of fortified and unfortified samples of DCV determine the 
percentage of added drug at each level. Good recoveries (100.5–102.73) 
were obtained at each added concentration, indicating that the method 
was accurate. Table 3 represents the percentage recovery for the drug.
Robustness
The robustness of the method was determined by purposely altering 
experimental condition. Three parameters selected were flow rate 
(± 0.1 ml/min), the wavelength change (±2 nm), and change in acetonitrile 
content in the mobile phase (±2%). While altering one set of condition, 
the other conditions were held constant at the optimum values. In all the 
Table 1: HPLC system suitability parameters
Code RT N Tf Rs
DP-1 2.3 2271 1.34 2.807
DP-2 3.1 3005 1.32 4.210
Daclatasvir 5.5 6142 1.29 -
RT: Retention time, N: Number of theoretical plates, Tf: USP tailing factor, 
Rs: USP resolution, DP: Degradation product, HPLC: High-performance liquid 
chromatography
Table 2: Precision studies
Concentration 
taken (μg/ml)






60 60.48±0.183, 0.302 59.988±0.413, 0.688
SD: Standard deviation, % RSD: Percentage relative standard deviation, 
n: Number of injections






± SD, RSD (%)
Recovery (%)
40 40.8±0.046, 0.156 102
60 61.64±0.187, 0.317 102.73
80 78.66±0.238, 0.265 100.56
n=3, SD: Standard deviation, % RSD: Percentage relative standard deviation
Table 4: Robustness results of DCV
Chromatographic changes
Factor Level RT Tf
A. Flow rate (ml/min)
0.7 −0.1 5.62 1.29
0.8 0 5.51 1.31
0.9 +0.1 5.42 1.30
Mean±% SD 5.517±0.10 1.30±0.01
B. Wavelength change (nm)
314 −2 5.57 1.29
316 0 5.65 1.30
318 +2 5.54 1.26
Mean±% SD 5.58±0.057 1.28±0.021
C. Percentage of acetonitrile in 
mobile phase (v/v)
48 −2 5.65 1.31
50 0 5.63 1.30
52 +2 5.60 1.28
Mean±% SD 5.62±0.025 1.29±0.015
n=3, RT: Retention time, Tf: USP tailing factor, n: Number of injections, 
SD: Standard deviation, DCV: Daclatasvir
Fig. 3: Chromatogram of tablet formulation of daclatasvir
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deliberately varied chromatographic conditions, no marked change in 
retention time and tailing factor of DCV is observed in Table 4.
System suitability test
The system suitability parameters with respect to resolution factor, 
theoretical plates, and tailing factor were calculated and are given in 
Table 1. It could be seen from the readings that the peaks of the drug 
and DP-1 and DP-2 were well resolved.
Degradation behavior
The drug was degraded in acidic hydrolytic condition (5 N) to 7.47% 
to form product 2, whereas in alkali stress condition (2 N), the drug 
degraded to 28% to form products 1 and 2. The DP 2 formed under 
both acidic and base hydrolytic conditions was overlapped in the 
chromatogram to show only one peak of product 2.
The chromatogram of mixture of stressed sample showing separation 
of drug and its DP is shown in Fig. 2. The drug was stable under all other 
stress conditions including heating in water, oxidation, photoexposure 
of solid drug, and dry heating at 80οC as shown in Table 5.
Study of the stability of commercial tablets
To study the assay content of DCV, tablets were prepared in house 
(60 mg) and were analyzed by the proposed method after exposure 
Scheme 1: Mass fragmentation pathway of degradation product-1
Table 5: Optimized stress conditions for DCV
Stressor Concentration of stressor Temperature and time % assay of active substance % degradation
Acid 5 N HCl 80°C for 4 h 92.53 7.47
Alkali 2 N NaOH 80°C for 1 h 72.04 27.96
Oxide 30% H2O2 RT for 7 days 96.07 3.93
Neutral H2O 80°C for 24 h 97.87 2.13
Heat 80°C 80°C for 1 h 97.05 2.95
Photodegradation UV (254 nm) 24 h 98.90 1.10
DCV: Daclatasvir
Fig. 4: Liquid chromatography–mass spectrometry chromatogram showing separation of daclatasvir and its degradation product 1 and 2 
in the mixture of stressed samples
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to accelerated storage condition (i.e., 40°C/75% RH). The peak was 
observed at retention time 5.58 min for the drug in the chromatogram 
of the drug samples extracted from tablets and no additional peak was 
found (Fig. 3). Experimental results are shown in Table 6 indicating 
that amount of DCV in tablets (% label claim) was in good agreement 
with the label claims, suggesting that there was no interference from 
any excipients, which are normally present in tablets and good quality 
packaging material was used. The statistical analysis is presented in 
Table 7.
Mass fragmentation pathway of the DPs
The mass fragmentation pathway was established from the results 
of LC-ESI-MS in positive mode. The positive ion MS spectrum of DCV 
exhibits a parent ion peak [M+H]+ of 739.38 (m/z) which corresponds 
to the theoretical value of molecular mass of DCV, i.e., 738.89 g/mol. 
To characterize the DPs, the stressed solution of DCV was subjected to 
LC–MS analysis. The resulted LC–MS chromatogram is shown in Fig. 4.
Postulated structure of DPs
DP-1 (m/z 681.39)
The LC-ESI-MS of the base hydrolytic degraded sample showed a parent 
ion peak at 681.39 m/z which supports the proposed structure of DP-1 




ESI-MS2 of [M+H]+ ion at m/z 681.39 shows abundant fragment ions at 
m/z 513.26 (loss of C9H18N2O, addition of 2H+ from m/z 681.39), and 
low abundance ion at m/z 565.29 (loss of C5H12N2O from m/z 681.39), 
m/z 408.22 (loss of C7H11NO3 from m/z 565.29), m/z 356.19 (loss of 
C7H12NO3 from m/z 513.26), and m/z 287.13 (loss of C4H8N from m/z 
356.19) (Fig. 5 and Scheme 1).
Postulated structure of DP-2 (m/z 582.32)
The product was exclusively seen in the +ESI mode (Fig. 4). DP-2 was 




The ESI-MS2 of [M+H]+ ion at m/z 582.32 shows abundant fragment 
ion at m/z 513.26 (loss of C4H9N, addition of 2H+ from m/z 582.32), 
Table 6: Results of analysis of tablet formulation
Tablet strength 60 mg
Weight of tablet powder 
taken (mg)










Fig. 5: Liquid chromatography–mass spectrometry and tandem mass spectrometry spectra of degradation product-1, respectively, 
+electrospray ionization mode
Table 7: Statistical validation of analysis of capsule formulation
Drug Amount of drug estimated (mg/tablet) % label claim* SD CV SE
Daclatasvir 61.086 101.81 0.304 0.309 0.074
*Average of six determinations. CV: Coefficient of variation, SD: Standard deviation, SE: Standard error
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Scheme 2: Mass fragmentation pathway of degradation product-2
Fig. 6: Liquid chromatography–mass spectrometry and tandem mass spectrometry spectra of degradation product-2, respectively, 
+electrospray ionization mode
along with its low abundance ion at m/z 70.07 (loss of C29H33N6O3+, 
from m/z 582.32), low abundance at m/z 565.29 (loss of NH3, from 
m/z 582.32) and, m/z 481.23 (loss of CH4O, from m/z 513.26), m/z 
356.19 (loss of C6H9NO2, addition of 2H+ from m/z 481.23), and m/z 
287.13 (loss of C4H8N, addition of H+ from m/z 356.19) (Fig. 6 and 
Scheme 2).
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CONCLUSION
According to ICH guidelines, stress degradation studies on DCV were 
carried out to provide information regarding degradation behavior 
of the drug. The drug was susceptible to acid and base hydrolytic 
degradation, whereas it was stable in all other conditions. Two DPs 
were formed and separated in a single run by an isocratic RP-HPLC 
method. The product was a new DP and was not reported in literature. 
The developed method proved to be simple, accurate, precise, specific, 
and robust. It was successfully employed for the analysis of the tablet 
formulation stored under accelerated conditions of temperature and 
humidity. The DPs were characterized with the help of LC–MS/MS 
and complete fragmentation pathways are proposed and shown in 
Scheme 1 and Scheme 2, respectively. Characterized DPs can help to 
synthesize reference standards and to observe their presence in the 
stability samples. This study discovered the useful information which 
is not still reported in literature of DCV. The developed method was 
found to be less time consuming as the drug gets eluted at 5.54 RT (less 
time of analysis) and cost effective and may be more advantageous for 
routine analysis of the drug in marketed formulation.
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